Provided by Tiger Fintech (Singapore) Pte. Ltd.

MiNK Therapeutics, Inc.

7.59
-0.0105-0.14%
Post-market: 7.590.00000.00%19:19 EDT
Volume:4.27K
Turnover:32.49K
Market Cap:30.10M
PE:-2.66
High:7.95
Open:7.56
Low:7.24
Close:7.60
Loading ...

MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report

GlobeNewswire
·
11 hours ago

MiNK Therapeutics Inc (INKT) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...

GuruFocus.com
·
19 Mar

MiNK Therapeutics Reports 2024 Progress and Financials

TIPRANKS
·
19 Mar

Q4 2024 Mink Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents
·
19 Mar

Buy Rating Affirmed for MiNK Therapeutics Amid Promising Clinical Developments and Strategic Expansion

TIPRANKS
·
19 Mar

Promising Clinical Data and Strategic Initiatives Drive Buy Rating for MiNK Therapeutics

TIPRANKS
·
18 Mar

Mink Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
18 Mar

MiNK Therapeutics Q4 2024 GAAP EPS $(0.62) Misses $(0.50) Estimate

Benzinga
·
18 Mar

Press Release: MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress

Dow Jones
·
18 Mar

Mink Therapeutics Inc expected to post a loss of 50 cents a share - Earnings Preview

Reuters
·
14 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
14 Mar

Mink Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

THOMSON REUTERS
·
04 Mar

MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

GlobeNewswire
·
04 Mar

Health Check:  Half-price sale as brokers ring the bell on Neuren shares

Stockheads
·
04 Mar

Promising Early Results from MiNK Therapeutics’ Phase 2 Study of agenT-797 in Refractory GEC Justify Buy Rating

TIPRANKS
·
25 Feb

MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting

GlobeNewswire
·
24 Feb

Mink Therapeutics Regains Full Compliance With Nasdaq Listing Requirements

THOMSON REUTERS
·
20 Feb

MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting

GlobeNewswire
·
13 Feb

Mink Therapeutics Inc trading halted, news pending

TIPRANKS
·
28 Jan

MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI

GlobeNewswire
·
24 Jan